Axial Spondyloarthritis (axSpA) is an umbrella term for a form of inflammatory form of arthritis associated with chronic lower back pain. There are two subtypes of axSpA: Non- radiographic Axial Spondyloarthritis (nr-axSpA), and Ankylosing Spondylitis (AS). Several symptoms of Axial Spondyloarthritis include pain in the lower back, weight loss, fatigue, tiredness, fever, and night sweats.
Currently, there are more than 45 drugs in the pipeline of Axial Spondyloarthritis treatment. About 2.7 million Americans or more are affected by Axial Spondyloarthritis and it is diagnosed by image testing. Aside from Axial Spondyloarthritis drugs, physical activity also plays an essential role in axSpA treatment.
DelveInsight brings into focus the current scenario of Axial Spondyloarthritis market landscape in the newsletter consisting of currently marketed axSpA drugs, market trends, historical and current epidemiology, ongoing research & development, upcoming novel drugs, and Axial Spondyloarthritis pipeline scenario. Learn more about the recent happenings, top-level collaborations, fundings, and significant breakthroughs in the Axial Spondyloarthritis space.
Track fresh updates in the Axial Spondyloarthritis market by downloading our newsletter; simply fill-up the form towards the right and stay in touch to learn more about our new offerings and services.
Join our Newsletter series and get rich insights delivered every week to you.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News Flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Axial Spondyloarthritis Market Dynamics
- Collaborations and deals in the domain